2020

On January 27, 2020, Endo begins shipment of an authorized generic version of Allergan’s Carafate^® (sucralfate) oral suspension 1gm/10 mL.

On March 6, 2020, Blaise Coleman becomes President and Chief Executive Officer of Endo.

On July 6, 2020, Endo announces that it received FDA approval of Qwo^® (collagenase clostridium histolyticum-aaes).

On September 25, 2020, Endo announces a non-exclusive agreement with Novavax, Inc. to provide fill-finish manufacturing services for Novavax’s COVID-19 vaccine candidate.

On December 2, 2020, Endo completes acquisition of BioSpecifics Technologies Corp.

2019

On April 5, 2019, Endo begins shipment of authorized generic version of Merck's PROVENTIL^® (albuterol sulfate) HFA Inhalation Aerosol, 120mcg.

On July 31, 2019, Endo and Helsinn announce agreement for Paladin Labs to commercialize Pracinostat in Canada.

On September 4, 2019, Endo announces approval of first generic Orfadin^® in U.S.

On November 4, 2019, Endo names Paul V. Campanelli Chairman, President and Chief Executive Officer of Endo.

On December 10, 2019, Endo begins shipment of the first generic version of Novartis’ Afinitor^® (everolimus) 2.5 mg, 5 mg and 7.5 mg tablets.

2018

In July 2018, Endo establishes Nevakar Licensing Agreement, development of 5 differentiated, 505(b)(2) sterile injectable products.

On November 7, 2018, Endo announces positive results from Phase 3 studies of collagenase clostridium histolyticum (CCH) in patients with cellulite.

2017

On February 28, 2017, Endo announces strategic change to unify its operating model, enhance the generics pipeline through investment in hard-to-produce assets & technologies, transform the branded business into a highly focused Specialty business and divest non-core assets.

On July 3, 2017, Endo completes its divestiture of Litha Healthcare Group to Acino Pharma AG.

On October 25, 2017, Endo completes its divestiture of Grupo Farmacéutico SOMAR to Advent International.

2016

On February 29, 2016, Endo announces the wind down of ASTORA Women’s Health Business (formerly AMS Women’s Health).

On September 27, 2016, Endo names Paul V. Campanelli President, Chief Executive Officer and a Director of Endo. 

On December 8, 2016, Endo makes a strategic decision regarding their U.S. branded pain business and returns BELBUCA™ to BioDelivery Sciences International, Inc. (BDSI). Endo’s remaining pain products, including OPANA® ER, will be part of Endo’s portfolio of established products and will no longer require promotional support. 

2015

On January 29, 2015, Endo acquires Auxilium Pharmaceuticals, Inc. as part of Endo Pharmaceuticals business.

On February 10, 2015, Endo completes acquisition of Litha Healthcare Group.

On August 4, 2015, Endo completes its divestiture of AMS Men’s and Prostate Health Businesses to Boston Scientific.

On September 28, 2015, Endo completes acquisition of specialty generics and sterile injectables company Par Pharmaceutical Holdings Inc. Par is combined with Qualitest to create expanded U.S. Generics business named Par Pharmaceutical.

On October 26, 2015, Endo announced that the U.S. Food and Drug Administration (FDA) approved BELBUCA™ (buprenorphine) buccal film for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

2014

On February 3, 2014, Endo successfully completed its acquisition of specialty generics company Boca Pharmacal. 

On February 3, 2014, Endo completed its divestiture of HealthTronics to Altaris Capital Partners, LLC.

On February 28, 2014, Endo completed its acquisition of Paladin Labs, a leading Canada-based specialty pharmaceutical company.

On February 28, 2014,  Endo and Paladin Labs came together under Endo International plc. Endo established new global headquarters in Dublin, Ireland.

In March 2014, U.S. FDA approved AVEED® (Testosterone Undecanoate) injectable testosterone replacement therapy for men living with hypogonadism, or Low-T

On July 24, 2014, Endo completed its acquisition of Grupo Farmaceutico Somar® (SOMAR), a leading, privately owned specialty pharmaceuticals company based in Mexico City.

On August 6, 2014, Endo completed its acquisition of DAVA Pharmaceuticals, Inc., a privately-held company specializing in generic pharmaceuticals. 

2013

In January 2013, Endo Corporate Headquarters moves from Chadds Ford to a newly constructed building at the Atwater Campus in Malvern, PA.

On February 25, Rajiv De Silva is named President, Chief Executive Officer and a Director of Endo.

In June 2013, Endo announces strategic change to focus on providing quality healthcare products through distinct operating companies, and announces restructuring to improve operating margins.

2012

In February 2012, Endo announces the aggregation of its operating companies as part of an enterprise-wide branding initiative; announces corporate name change to Endo Health Solutions.

December 2012, Endo’s board announces the retirement of President and CEO Dave Holveck.

2011

On January 28, 2011, Endo enters into a collaboration agreement with Orion Corporation for the discovery, development and commercialization of assets in Oncology.

On March 3, 2011, Endo Launches FORTESTA® (Testosterone) Gel.

On June 20, 2011, American Medical Systems Inc (AMS) becomes a wholly owned subsidiary of Endo Pharmaceuticals.

2010

On July 15,2010, HealthTronics, Inc. becomes an affiliate of Endo Pharmaceuticals.

On November 4, 2010, Penwest Pharmaceuticals becomes a wholly owned subsidiary of Endo Pharmaceuticals.

On December 1, 2010, Qualitest Pharmaceuticals becomes a wholly owned subsidiary of Endo Pharmaceuticals.

On December 29, 2010, the U.S. Food and Drug Administration approved FORTESTA® Gel.

2009

On March 23, 2009, Endo Pharmaceuticals successfully completed its acquisition of Indevus Pharmaceuticals, Inc. Indevus brought us multiple marketed products that enhance revenue growth, a specialized infrastructure focused in urology, endocrinology and oncology, and a strong drug-development pipeline.

Endo relaunches VALSTAR^®.

2008

Endo entered into a licensing agreement with Novartis to obtain the exclusive U.S. marketing rights for the prescription medicine Voltaren^® Gel (diclofenac sodium topical gel) 1%. Voltaren Gel received regulatory approval in October 2007 from the U.S. Food and Drug Administration.

David Holveck is named President, Chief Executive Officer and a Director of Endo. A new executive team is created to take Endo to the next level.

2007

Roger Kimmel appointed chairman of the Board; Carol Ammon retired.

Endo entered into a license and development agreement with Alexza Pharmaceuticals, Inc. for the exclusive clinical development and commercialization rights in North America for Alexza's AZ-003/ EN3294. Currently in Phase I, clinical development, AZ-003 is a hand-held drug device system that uses Alexza's proprietary Staccato^® system inhalation technology to deliver fentanyl.

2006

Endo received FDA approval for OPANA^® and OPANA^® ER, which represented the first internally developed NDAs to be granted FDA approval.

Endo Pharmaceuticals acquires RxKinetix Inc. through an acquisition. The acquisition broadens Endo pipeline with supportive care oncology products, including EN3285, a topical oral-rinse for the prevention of oral mucositis.

2005

Endo Pharmaceuticals acquired exclusive licenses from DURECT Corporation to develop and commercialize a seven-day transdermal sufentanil patch (EN3270).

2004

Endo entered into an agreement with Vernalis for the exclusive rights to market FROVA^® in North America. Launched in the U.S. in June 2002.

2003

Endo further expands its internal sales force by converting the contract pharma sales force, district managers and regional directors to full-time Endo employees.

2002

Endo established its first internal sales force when it converted the contract specialty sales force and district managers into full-time employees to concentrate sales efforts.

Endo reached $1 billion dollars in cumulative sales.

2001

Endo receives FDA approval for PERCOCET^® strengths (7.5/325 and 10/325 oxycodone/acetaminophen).

2000

Endo Pharmaceuticals acquired Algos Pharmaceutical Corporation through a merger. As a result of this merger, Endo Pharmaceuticals became a publicly traded company, under the NASDAQ symbol ENDP.

1999

Endo launched three strengths of its leading brand-name drug PERCOCET^®. After receiving FDA approval, Endo launched LIDODERM^® as its first proprietary, patented product.

1998

Endo licensed LIDODERM® from Hind Healthcare.

1997

Three executives of DuPont Merck acquired certain products from DuPont Merck in a management buyout for $277 million with financing from Kelso & Company, a private equity investment firm purchased all of Endo Laboratories L.L.C.'s generic products along with 12 important brand products, including PERCOCET^® and PERCODAN^®.

Intravenous Products of America, Inc. changed its name to Endo Products

The history of Endo can be traced back to 1920 to a family-run pharmaceutical company originally called Intravenous Products of America, Inc. In 1935 Intravenous Products of America, Inc. changed its name to Endo Products.

In 1950, PERCODAN^® was launched.

In 1969, E.I. du Pont de Nemours and Company (DuPont) acquired Endo. In 1971, PERCOCET^® was launched.

In 1994, DuPont Merck reestablished Endo as a separate entity within the company. This entity was named Endo Laboratories L.L.C. and served as DuPont Merck's generic division.